Please login to the form below
Boehringer Ingelheim's Dr Susan Anton joins Icon
The CRO also appoints Dr Pui Leung, boosting its early phase and epidemiology and risk management teams
Icon has appointed former Boehringer Ingelheim director Dr Susan Anton to head up its epidemiology and risk management practice.
The move is one of two senior appointments at the contract research organisation (CRO), which also see Dr Pui Leung join at a senior clinical research physician.
Dr Anton has more than 25 years of experience leading international epidemiologic, health economic, and outcomes research, and other market access initiatives.
Most recently she served as director of US medical outcomes research and registries at Boehringer Ingelheim, and prior to that directed health economic, epidemiologic and outcomes research efforts across therapeutic areas at Bristol-Myers Squibb.
Meanwhile, Dr Leung, who will be based at Icon's clinical pharmacology unit in Manchester, UK, has 10 years of experience as a senior phase I clinical research physician in two UK CROs.
Before joining the pharmaceutical industry in 2002, he spent 13 years as a hospital physician in the UK's National Health Service (NHS).
Share
Related Hub content
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
Say Communications
We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
